ଡାପ୍ଟୋମାଇସିନ

ଡାପ୍ଟୋମାଇସିନ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଏକ ବେପାର ନାମ କ୍ୟୁବିସିନ, ହେଉଛି ଏକ ଆଣ୍ଟିବାୟୋଟିକ ଯାହା ମେଥିସିଲିନ-ପ୍ରତିରୋଧୀ ସ୍ଟାଫିଲୋକୋକସ ଅରିଅସ (MRSA) ଭଳି ଗ୍ରାମ-ପଜିଟିଭ ଜୀବାଣୁଦ୍ୱାରା ସୃଷ୍ଟି ହୋଇଥିବା ଗୁରୁତର ସଂକ୍ରମଣର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ । ^[7] ଏହା ଏକ ଶିରାରେ ଇଞ୍ଜେକସନ ଆକାରରେ ଦିଆଯାଏ ।^[7]

ଡାପ୍ଟୋମାଇସିନ

Clinical data
Trade names	Cubicin, Cubicin RF, others
Synonyms	LY 146032
AHFS/Drugs.com	monograph
data	EU EMA: yes US DailyMed: Daptomycin
Pregnancy category	AU: B1 [1] US: N (Not classified yet) [1]
Routes of administration	Intravenous
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) [2] US: ℞-only [3][4] EU: Rx-only [5]
Pharmacokinetic data
Bioavailability	n/a
Protein binding	90–95%
Metabolism	Renal (speculative)[6]
Elimination half-life	7–11 hours (up to 28 hours in renal impairment)
Excretion	Kidney (78%; primarily as unchanged drug); faeces (5.7%)
Identifiers
IUPAC name N-Decanoyl-L-tryptophyl-L-asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine[egr]1-lactone
ECHA InfoCard	100.116.065
Chemical and physical data
Formula	C72H101N17O26
Molar mass	୧,୬୨୦.୬୯ g·mol−1
InChI InChI=1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45+,46+,47+,48+,49+,50-,60+,61+/m1/s1 --> N Key:DOAKLVKFURWEDJ-RWDRXURGSA-N Y
(verify)

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ତରଳ ଝାଡ଼ା, ମୁଣ୍ଡବିନ୍ଧା, ରାସ, ଯକୃତ ସମସ୍ୟା, ମାଂସପେଶୀ ନଷ୍ଟ ହେବା ଏବଂ ଗଲୁ ହୋଇପାରେ ।^[7] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ କବକ ସଂକ୍ରମଣ, ଇଞ୍ଜେକସନ ନେଇଥିବା ସ୍ଥାନରେ ଯନ୍ତ୍ରଣା ଏବଂ ଆଲର୍ଜି ପ୍ରତିକ୍ରିୟା ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ । ^[8] ଏହା ଏକ ଲାଇପୋପେପ୍ଟାଇଡ୍ ଯାହା କେତେକ ବ୍ୟାକ୍ଟେରିଆର ଜୀବକୋଷ ଝିଲ୍ଲି ପରିବର୍ତ୍ତନ କରି କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ ।^[7]

୨୦୦୩ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏବଂ ୨୦୦୬ ମସିହାରେ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଡାପ୍ଟୋମାଇସିନ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^{[7] [8]} ସ୍ଟ୍ରେପ୍ଟୋମାଇସେସ ରୋଜିଓସ୍ପୋରସରୁ ପ୍ରାକୃତିକ ଉପାୟରେ ପ୍ରସ୍ତୁତ ହୁଏ ।^[9] ୨୦୧୯ ମସିହାରେ ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନର ଜରୁରୀ ଔଷଧ ତାଲିକାରୁ ଏହାକୁ ହଟାଇ ଦିଆଯାଇଥିଲା ।^{[10] [11]} ତଥାପି ଏହା ମାନବ ଔଷଧ ଭାବରେ ଗୁରୁତ୍ୱପୂର୍ଣ୍ଣ ।^[12]

ଆଧାର

1. "Daptomycin Use During Pregnancy". Drugs.com. 3 December 2019. Archived from the original on 21 October 2020. Retrieved 28 August 2020.
2. "Cubicin 350 mg powder for solution for injection or infusion - Summary of Product Characteristics (SmPC)". (emc). 24 August 2018. Archived from the original on 4 August 2020. Retrieved 28 August 2020.
3. "Cubicin- daptomycin injection, powder, lyophilized, for solution". DailyMed. 18 December 2018. Archived from the original on 25 March 2021. Retrieved 28 August 2020.
4. "Cubicin RF- daptomycin injection, powder, lyophilized, for solution". DailyMed. 18 December 2018. Archived from the original on 26 March 2021. Retrieved 28 August 2020.
5. "Cubicin". European Medicines Agency. 17 September 2018. Archived from the original on 26 October 2020. Retrieved 28 August 2020.
6. Woodworth JR, Nyhart EH, Brier GL, Wolny JD, Black HR (February 1992). "Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers". Antimicrobial Agents and Chemotherapy. 36 (2): 318–25. doi:10.1128/aac.36.2.318. PMC 188435. PMID 1318678.
7. "Daptomycin Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 4 March 2021. Retrieved 22 July 2021.
8. "Cubicin". Archived from the original on 26 October 2020. Retrieved 22 July 2021.
9. Nieder, Rolf; Benbi, Dinesh K.; Reichl, Franz X. (10 January 2018). Soil Components and Human Health (in ଇଂରାଜୀ). Springer. p. 64. ISBN 978-94-024-1222-2. Archived from the original on 29 August 2021. Retrieved 22 July 2021.
10. World Health Organization (2019). Executive summary: the selection and use of essential medicines 2019: report of the 22nd WHO Expert Committee on the selection and use of essential medicines. Geneva: World Health Organization. hdl:10665/325773. WHO/MVP/EMP/IAU/2019.05. License: CC BY-NC-SA 3.0 IGO.
11. World Health Organization (2019). The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl:10665/330668. ISBN 9789241210300. ISSN 0512-3054. WHO technical report series;1021.
12. World Health Organization (2019). Critically important antimicrobials for human medicine (6th revision ed.). Geneva: World Health Organization. hdl:10665/312266. ISBN 9789241515528.